Nasal Spray – BiotechReality – Information Intelligence System for Biopharma

Mass General Brigham researchers have developed a new nasal spray that will transport therapeutic genes straight to the lungs and airways, marking a major breakthrough in the field of gene therapy. According to a recent press release, this novel strategy has the potential to completely transform the way that a number of crippling respiratory disorders, such as cystic fibrosis and other inherited lung diseases, are treated. The novel delivery method addresses a long-standing issue in gene therapy for lung conditions: effectively and securely getting to the target cells inside the intricate respiratory system architecture. The effectiveness of delivery, immunological reactions, and the capacity to deliver treatment repeatedly have all been problems for traditional approaches. A multidisciplinary team at Mass General Brigham's research institutes created this intriguing treatment, which makes use of a specially designed viral vector, a benign virus that has been altered to convey therapeutic genetic information. The vector is made to efficiently pass through the nasal passages' mucosal barrier and descend to the lungs, where it will transfer its genetic payload to the cells that line the airways. Although the news release doesn't say which specific diseases are being studied or what stage clinical trials are in, the research suggests a less invasive and possibly more successful method of fixing genetic flaws that underlie a number of lung disorders. The therapy's ability to be administered with a straightforward nasal spray has a major benefit for patient comfort and usability, possibly enabling repeated dosage if needed without requiring more involved procedures. Potential Benefits Targeted Delivery: By delivering medication directly to the impacted lung cells and airway, the nasal spray technique may improve effectiveness and lessen systemic side effects. Non-Invasive Administration: A major advancement over more intrusive delivery techniques, improving patient comfort and compliance. Broad Applicability: The platform may be modified for a number of hereditary lung disorders, albeit precise initial targets have not yet been thoroughly described. Potential for Repeat Dosing: The vector's and the delivery system's design may permit repeated doses, which is essential for the treatment of long-term illnesses. The project's researchers are hopeful about the therapy's prospects. This discovery is a significant advancement, even if it is acknowledged that more investigation and clinical testing are required to verify its safety and effectiveness in people. The development demonstrates Mass General Brigham's dedication to developing cutting-edge therapies for difficult illnesses. In order to properly evaluate the long-term potential of this nasal spray gene therapy, the scientific community will be anxiously expecting peer-reviewed publications and more data from ongoing trials. If effective, this strategy might provide millions of people with lung conditions that are currently incurable fresh hope. As the study goes on, more information about the precise genetic targets and the projected timeframe for possible clinical application will become available. Source: Mass General BrighamJournal Reference: Yang, Zhi et al. “Cross-species tropism of AAV.CPP.16 in the respiratory tract and its gene therapies against pulmonary fibrosis and viral infection.” Cell reports. Medicine, 102144. 14 May. 2025, DOI: 10.1016/j.xcrm.2025.102144 Last Modified:

Tag: Nasal Spray

Mass General Brigham’s Breakthrough Gene Therapy Through Nasal Spray Shows Promising Results for Lung Diseases

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment